Thrombolytic Science, LLC (TSI) is a private, clinical stage

biopharmaceutical A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, t ...

company that was founded in 2006 based on the research of Harvard scientist Victor Gurewich into the potential use of prourokinase to break up blood clots. Gurewich co-founded the company and the founding CEO is business person Alexis Wallace. TSI's lead drug candidate is a synergistic sequential dual therapy

combination In mathematics, a combination is a selection of items from a set that has distinct members, such that the order of selection does not matter (unlike permutations). For example, given three fruits, say an apple, an orange and a pear, there are th ...

of mutant prourokinase (the precursor form of urokinase) and a small dose of tPA issue Plasminogen Activator TSI is developing its dual therapy as a potential treatment for conditions caused by blood clots, initially for

ischemic stroke A stroke is a medical condition in which poor blood flow to the brain causes cell death. There are two main types of stroke: ischemic, due to lack of blood flow, and hemorrhagic, due to bleeding. Both cause parts of the brain to stop functionin ...

and heart attacks. The company completed a Phase I trial in The Netherlands in 2017. The company raised $8 million by 2012 mostly from an undisclosed angel investor.

References

{{Reflist

External links

TSI website
Biotechnology companies of the United States Privately held companies based in Massachusetts Companies based in Cambridge, Massachusetts